Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Events


Current Treatments for VL


The number of treatments has increased in the past decade, but there are numerous drawbacks to each, such as difficulty in administration, length of treatment, toxicity, cost, and increasing parasitic resistance.

Pentavalent antimonials
remain the first-line treatment in most parts of the world, except in Bihar State, India where there is a high level of resistance. However, there has been significant improvement in the number of treatments available for VL during the past decade, with both new drugs and new formulations of old drugs either recently approved or in clinical trials.


Read more

Current Treatments for CL


There is currently no satisfactory treatment for any form of CL. Many treatment regimens are associated with significant failure rates and considerable toxicity. Relapses are common and there are increasing reports of drug resistance emergence.

Pentavalent antimonials (i.e. Sodium stibogluconate or meglumine antimonite) are given as first-line drugs through a series of intramuscular, intravenous, or intralesional injections. These drugs have serious side effects, require long treatment, are not affordable for most patients and are difficult to administer in poor rural areas.

Read more



Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License